SKF-86002

A cell-permeable, reversible, and ATP-competitive cytokine-suppressive anti-inflammatory drug (CSAID). A bicyclic imidazole that inhibits lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production (IC₅₀ = 1 µM). Also acts as an inhibitor of both cyclooxygenase and 5-lipoxygenase. SKF-86002 also acts as a specific p38 MAP kinase inhibitor.

A cytokine-suppressive anti-inflammatory drug (CSAID). A bicyclic imidazole that inhibits lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production (IC₅₀ = 1 µM). Also acts as an inhibitor of both cyclooxygenase and 5-lipoxygenase. SKF-86002 also acts as a specific p38 MAP kinase inhibitor.

Cell permeable: yes

Primary Target
(LPS)-stimulated IL-1 and TNF-α production

Product competes with ATP.

Reversible: yes

Target IC₅₀: 1 µM inhibiting lipolysaccharide (LPS)-stimulated human monocyte IL-1 and TNF-α production

Frasch, S.C., et al. 1998. J. Biol. Chem. 273, 8389.
Blanque, R., et al. 1997. Drugs Exp. Clin. Res. 23, 63.
Lee, J.C., et al. 1995. Nature 372, 739.
Prichett, W., et al. 1995. J. Inflamm. 45, 97.
Lee, J.C., et al. 1993. Ann. N.Y. Acad. Sci. 696, 149.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Irritant (B)